	US 12,227,774 B2
	Modified PHI29 DNA polymerases and uses thereof
Souad Naji, La Jolla, CA (US); Alexander Sevy, San Diego, CA (US); Jason Cellitti, San Diego, CA (US); Eli N. Glezer, Del Mar, CA (US); Bruna Krebs Kutche, San Diego, CA (US); Zachary Terranova, San Diego, CA (US); and Sumit Handa, San Diego, CA (US)
Assigned to Singular Genomics Systems, Inc., San Diego, CA (US)
Filed by Singular Genomics Systems, Inc., San Diego, CA (US)
Filed on May 9, 2024, as Appl. No. 18/659,585.
Application 18/659,585 is a continuation of application No. PCT/US2023/075838, filed on Oct. 3, 2023.
Claims priority of provisional application 63/378,223, filed on Oct. 3, 2022.
Claims priority of provisional application 63/493,180, filed on Mar. 30, 2023.
Claims priority of provisional application 63/502,005, filed on May 12, 2023.
Claims priority of provisional application 63/580,874, filed on Sep. 6, 2023.
Prior Publication US 2024/0294887 A1, Sep. 5, 2024
Int. Cl. C12N 9/12 (2006.01); C12Q 1/6844 (2018.01)

CPC C12N 9/1252 (2013.01) [C12Q 1/6844 (2013.01); C12Y 207/07007 (2013.01)]

20 Claims

1. A polymerase comprising an amino acid sequence that is at least 85% identical to SEQ ID NO: 1; comprising a proline, tryptophan, phenylalanine, tyrosine, alanine, or glycine at an amino acid position corresponding to position 216 of SEQ ID NO:1.